|
1
|
Okato A, Goto Y, Kurozumi A, Kato M,
Kojima S, Matsushita R, Yonemori M, Miyamoto K, Ichikawa T and Seki
N: Direct regulation of LAMP1 by tumor-suppressive microRNA-320a in
prostate cancer. Int J Oncol. 49:111–122. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Coleman RE: Clinical features of
metastatic bone disease and risk of skeletal morbidity. Clin Cancer
Res. 12:6243s–6249s. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Edlind MP and Hsieh AC: PI3K-AKT-mTOR
signaling in prostate cancer progression and androgen deprivation
therapy resistance. Asian J Androl. 16:378–386. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Watson PA, Arora VK and Sawyers CL:
Emerging mechanisms of resistance to androgen receptor inhibitors
in prostate cancer. Nat Rev Cancer. 15:701–711. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hu Y, Zhao Q, Rao J, Deng H, Yuan H and Xu
B: Longitudinal trends in prostate cancer incidence, mortality, and
survival of patients from two Shanghai city districts: A
retrospective population-based cohort study, 2000–2009. BMC Public
Health. 14:3562014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Khan S, Brougham CL, Wall D, Newell J,
Kerin MJ and Dwyer RM: Mir-339-5p acts as A tumour suppressor in
breast cancer, mediated at least in part through regulation of cell
proliferation. Ir J Med Sci. 182:S3432013.
|
|
9
|
Wang T, Ren Y, Liu R, Ma J, Shi Y, Zhang L
and Bu R: miR-195-5p suppresses the proliferation, migration and
invasion of oral squamous cell carcinoma by targeting TRIM14.
Biomed Res Int. 2017:73781482017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Alipour A, Mojdehfarahbakhsh A, Tavakolian
A, Morshedzadeh T, Asadi M, Mehdizadeh A and Nami M: Neural
communication through theta-gamma cross-frequency coupling in a
bistable motion perception task. J Integra Neurosci. 15:539–551.
2016. View Article : Google Scholar
|
|
11
|
Wang D, Lu G, Shao Y and Xu D:
microRNA-802 inhibits epithelial-mesenchymal transition through
targeting flotillin-2 in human prostate cancer. Biosci Rep. 37:pii:
BSR20160521. 2017. View Article : Google Scholar
|
|
12
|
Liu C, Liu R, Zhang D, Deng Q, Liu B, Chao
HP, Rycaj K, Takata Y, Lin K, Lu Y, et al: MicroRNA-141 suppresses
prostate cancer stem cells and metastasis by targeting a cohort of
pro-metastasis genes. Nat Commun. 8:142702017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kong Q, Chen XS, Tian T, Xia XY and Xu P:
MicroRNA-194 suppresses prostate cancer migration and invasion by
downregulating human nuclear distribution protein. Oncol Rep.
37:803–812. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li JZ, Li J, Wang HQ, Li X, Wen B and Wang
YJ: MiR-141-3p promotes prostate cancer cell proliferation through
inhibiting kruppel-like factor-9 expression. Biochem Biophys Res
Commun. 482:1381–1386. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang J, Liang J and Huang J:
Downregulated microRNA-26a modulates prostate cancer cell
proliferation and apoptosis by targeting COX-2. Oncol Lett.
12:3397–3402. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yang J, Fan B, Zhao Y and Fang J:
MicroRNA-202 inhibits cell proliferation, migration and invasion of
glioma by directly targeting metadherin. Oncol Rep. 38:1670–1678.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Meng X, Chen X, Lu P, Ma W, Yue D, Song L
and Fan Q: miR-202 promotes cell apoptosis in esophageal squamous
cell carcinoma by targeting HSF2. Oncol Res. 25:215–223. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Damavandi Z, Torkashvand S, Vasei M,
Soltani BM, Tavallaei M and Mowla SJ: Aberrant expression of breast
development-related MicroRNAs, miR-22, miR-132, and miR-212, in
breast tumor tissues. J Breast Cancer. 19:148–155. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Han SY, Han HB, Tian XY, Sun H, Xue D,
Zhao C, Jiang ST, He XR, Zheng WX, Wang J, et al: MicroRNA-33a-3p
suppresses cell migration and invasion by directly targeting PBX3
in human hepatocellular carcinoma. Oncotarget. 7:42461–42473.
2016.PubMed/NCBI
|
|
21
|
Sun Z, Zhang T, Hong H, Liu Q and Zhang H:
miR-202 suppresses proliferation and induces apoptosis of
osteosarcoma cells by downregulating Gli2. Mol Cell Biochem.
397:277–283. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang Y, Zheng DY, Xiong Y, Xue C, Chen G,
Yan B and Ye Q: miR-202 suppresses cell proliferation in human
hepatocellular carcinoma by downregulating LRP6
post-transcriptionally. FEBS Lett. 588:1913–1920. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang Q, Huang Z, Guo W, Ni S, Xiao X, Wang
L, Huang D, Tan C, Xu Q, Zha R, et al: microRNA-202-3p inhibits
cell proliferation by targeting ADP-ribosylation factor-like 5A in
human colorectal carcinoma. Clin Cancer Res. 20:1146–1157. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhao Y, Li CL, Wang M, Su L, Qu Y, Li J,
Yu B, Yan M, Yu Y, Liu B and Zhu Z: Decrease of miR-202-3p
expression, a novel tumor suppressor, in gastric cancer. PLoS One.
8:e697562013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chang F, Lee JT, Navolanic PM, Steelman
LS, Shelton JG, Blalock WL, Franklin RA and McCubrey JA:
Involvement of PI3K/Akt pathway in cell cycle progression,
apoptosis, and neoplastic transformation: A target for cancer
chemotherapy. Leukemia. 17:590–603. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Osaki M, Oshimura M and Ito H: PI3K-Akt
pathway: Its functions and alterations in human cancer. Apoptosis.
9:667–676. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Nicholson KM and Anderson NG: The protein
kinase B/Akt signalling pathway in human malignancy. Cell Signal.
14:381–395. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Woo SU, Sangai T, Akcakanat A, Chen H, Wei
C and Meric-Bernstam F: Vertical inhibition of the PI3K/Akt/mTOR
pathway is synergistic in breast cancer. Oncogenesis. 6:e3852017.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chai R, Fu L, Zheng Z, Liu T, Ji S and Li
G: Resveratrol inhibits proliferation and migration through SIRT1
mediated post-translational modification of PI3K/AKT signaling in
hepatocellular carcinoma cells. Mol Med Report. 16:8037–8044. 2017.
View Article : Google Scholar
|
|
30
|
Chen R, Li Y, Buttyan R and Dong X:
Implications of PI3K/AKT inhibition on REST protein stability and
neuroendocrine phenotype acquisition in prostate cancer cells.
Oncotarget. 8:84863–84876. 2017.PubMed/NCBI
|
|
31
|
Agell L, Hernández S, Salido M, de Muga S,
Juanpere N, Arumí-Uria M, Menendez S, Lorenzo M, Lorente JA,
Serrano S and Lloreta J: PI3K signaling pathway is activated by
PIK3CA mRNA overexpression and copy gain in prostate tumors, but
PIK3CA, BRAF, KRAS and AKT1 mutations are infrequent events. Mod
Pathol. 24:443–452. 2011. View Article : Google Scholar : PubMed/NCBI
|
